NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I'm certainly no expert and like to express things in a simple way that may not be technically correct, but I believe that BP's developing what they found in all patients, but most patients have 20 of them. A BP will design a vaccine that may contain say the 30 most common of these markers and develop a way to mass produce it, and it meets their definition of being a vaccine personalized for that form of cancer. A patient with enough of those 30 marker should see some benefits.

In our case, our vaccine is made from the patients cancers, if that cancer has 20 markers, the vaccine will have those 20 markers. If the patient has 10, it will have 10, or if it has 30, it will have 30.

What do you think will be more effective, a mass produced vaccine that might hit half the markers in the cancer, or a personalized vaccine that hits all markers found in the cancer. I believe the answer is obvious. Certainly, treatment with a mass produced vaccine may be cheaper, but the personalized vaccine should be so far more effective that the price difference should be more than offset by the effectiveness.

Gary